Brandweek on AZ: "the mainstream media has had its lunch eaten by Rost et al on this story"
At AZ, a Potential Smoking Gun Emerges in the Bucket of Money Scandal
Peter Rost this morning posted what appears to be an inexplicable set of PowerPoint slides from the AZ Group of 7 whistleblowers. The entire slideshow (see download below) is a comparison of AZ's Arimidex anti-cancer drug vs. Novartis' Femara drug. I hope I don't have to remind you at this stage that it is against AZ's internal policy (which in turn is controlled by its corporate integrity agreement with the government over the Zoldex scandal), to market Arimidex in comparison to Femara. Especially as the two drugs have never, according to Rost and his sources, gone head-to-head in proper study.
Jim continues with an interesting analysis, including agreeing with what I wrote about AstraZeneca's response:
"This is what good crisis PR looks like. They're not ducking it, spinning it or pretending it doesn't exist. Yes, it is going to suck at AZ for a while, but if the company can be seen to be doing the right thing and not trying to persuade us all that this is somehow 'not a story,' then it will be over faster and with less lasting damage."
Jim also writes, "the mainstream media has had its lunch eaten by Rost et al on this story. Given that it involves breast cancer, breaking the law, and greed ... it's a matter of time before the big boys wade in."
Read Jim's article here.